Molecular Therapy — Nucleic Acids · 2021 · 34 citations · 46 references
MedicineMolecular BiologyMolecular MedicineCell SignalingGene ExpressionGene TherapyExtracellular MatrixMuscle DisordersMuscle PathologyMuscle PhysiologyMuscle TissueMuscular DystrophyAntisense RnasMuscle Gene DeliveryMuscular Dystrophy PathophysiologyReduced Grip StrengthSkeletal Muscle TargetingSystemic DeliverySystemic Drug DeliveryTargeted Molecular Therapy
target gene expression in skeletal muscles. In addition, the DUX4 ASO alleviated the severity of skeletal muscle pathology and partially prevented the dysregulation of inflammatory and extracellular matrix genes. DUX4 ASO-treated ACTA1-MCM;FLExDUX4 mice performed better on a treadmill; however, the hanging grid and four-limb grip strength tests were not improved compared to control ASO-treated ACTA1-MCM;FLExDUX4 mice. This study shows that systemic delivery of ASOs targeting DUX4 is a promising therapeutic strategy for FSHD and strategies that further improve the ASO efficacy in skeletal muscle are warranted.
46
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
Eugenio Mercuri, Basil T. Darras, Claudia A. Chiriboga et al. · New England Journal of Medicine · 2018 · 1.4K citations · Full text
Medicine, Neurology, Neuroscience +17
Eteplirsen for the treatment of Duchenne muscular dystrophy
Jerry R. Mendell, Louise R. Rodino‐Klapac, Zarife Sahenk et al. · Annals of Neurology · 2013 · 795 citations · Full text
A Unifying Genetic Model for Facioscapulohumeral Muscular Dystrophy
Richard J.L.F. Lemmers, Patrick J. van der Vliet, Rinse Klooster et al. · Science · 2010 · 783 citations · Full text